Professor Geoff Hackett and Professor Mike Kirby summarise updated guidance on diagnosing and treating erectile dysfunction in primary care and the importance of investigating for cardiovascular risk factors
Read this article to learn more about:
- how changes in prescribing regulations affect management of erectile dysfunction (ED)
- ED as a risk factor for cardiovascular disease and other conditions
- diagnosing and treating ED.
After reading this article, ‘ Test and reflect ’ on your updated knowledge with our multiple-choice questions. We estimate that this activity will take you 30 minutes—worth 0.5 CPD credits.
Increased media interest regarding the availability of safe and effective oral drugs for erectile dysfunction (ED) has resulted in more men seeking help for this condition, with 1 in 4 new diagnoses being in men aged under 40 years.1,2
Newer treatment options reduce the need for urological referral, so that management of ED now mainly falls within the remit of primary care or specialist’s men’s health physicians, who also need to be alert to links between ED and cardiometabolic disease3 and the importance of relationship and psychological issues.4 With the recent availability of over-the-counter medication, pharmacists now have an important role in the assessment of associated co-morbidities to ensure safe and appropriate dispensing. The pharmacists are trained to exclude inappropriate use and to signpost the patient to get appropriate investigations.
The British Society for Sexual Medicine has updated its guideline on the management of ED4 to help physicians and other healthcare professionals manage ED in line with recent evidence and clinical opinion, while adhering to Department of Health regulations.
Erectile dysfunction is the continuing inability to achieve and/or maintain an erection sufficient for sexual performance.4 ED results from disruption of various vascular, neuronal, hormonal, and metabolic factors, mediated by endothelial and smooth muscle dysfunction.4
Erectile dysfunction is associated with a number of important physical conditions and may affect psychosocial health. This can result in reduced quality of life in men and for their partners.5
Erectile dysfunction has similar risk factors to cardiovascular disease (CVD);6,7 see Box 1.
Box 1: Risk factors for erectile dysfunction4,6
- Older age
- Sedentary lifestyle
- Metabolic syndrome
Erectile dysfunction as a risk factor
Erectile dysfunction reflects endothelial dysfunction and is a cardiovascular (CV) risk factor itself, conferring a risk equivalent to current moderate smoking.4
Erectile dysfunction is also an important marker of future CV risk and may precede a CV event by some 2–5 years.6,7
The predictive value of ED and coronary artery disease may be particularly useful in younger men (aged 40–49 years),8 in whom traditional risk assessment tools are less helpful.
Other benefits of case finding erectile dysfunction in practice
Case finding ED in practice facilitates the early diagnosis and management of other conditions, such as dyslipidaemia, diabetes, hypogonadism, occult cardiac disease, and lower urinary tract symptoms (LUTS)/benign prostatic hyperplasia (BPH).4
While the degree of dyslipidaemia may not dictate treatment with lipid lowering therapy according to primary prevention guidelines, it may be a major reversible component in ED.3
Erectile dysfunction may be the first symptom in up to one-fifth of men with diabetes.3 It may also be a better predictor of cardiovascular events in these patients than hypertension, dyslipidaemia, and microalbuminuria.9
Testosterone deficiency (TD)10 is a reversible cause of ED that may make men less- or even non-responsive to phosphodiesterase type 5 inhibitors (PDE5Is).3,4 It is also associated with other long-term health implications such as type 2 diabetes, metabolic syndrome, obesity, and depression.11
In an otherwise asymptomatic man, ED may reflect underlying coronary artery disease.3 Erectile dysfunction is also associated with ischaemic heart disease severity, in terms of plaque burden and number of arteries affected.6,7
Lower urinary tract symptoms (LUTS) and ED severity are closely related, and therapies for one may adversely or beneficially affect the other.12,13 A study comparing daily tadalafil 5 mg versus placebo and tamsulosin 400 mg versus placebo showed that, while both drugs equally improved LUTS, tadalafil 5 mg also improved erectile dysfunction symptoms.14 Alpha-blockers have been estimated to produce anejaculation or retrograde ejaculation in up to 30% of men treated for LUTS.15
Diagnosing erectile dysfunction
The initial assessment of ED should include a comprehensive medical, sexual, and relationship history. Clinically validated questionnaires can be used to assess sexual function domains and response to therapies.4 It may be helpful to have the man’s partner present in the consultation, so that any co-existing sexual problems on their part can also be identified and addressed.
A careful physical examination is important, to detect any potentially reversible causes of ED. Routine laboratory testing for ED includes lipid profile, fasting glucose and/or glycated haemoglobin, and fasting testosterone level.4
Testosterone levels should be checked before 11.00 in the morning and measured on at least two separate occasions.4 Free testosterone has a greater correlation with clinical symptoms of TD.16 This can be calculated from total testosterone, sex-hormone binding globulin, and albumin levels. The Primary Care Testosterone Advisory Group provides a free and bioavailable testosterone calculator and downloadable app. If results are abnormal, consider discussion with or referral to a specialist clinic.4
Specialist investigations include the intra-cavernous injection test, colour Doppler ultrasound, phalloarteriography, cavernosometry/cavernosography, and nocturnal penile tumescence and rigidity.4 Most men with ED do not require these tests. Some patients, however, want to establish the cause of their ED and should be investigated appropriately. Other indications for specialist investigations include patients who:4
- have penile or testicular deformities that require assessment
- have a history of trauma
- have an arterial abnormality on Doppler ultrasound
- are young and have always had trouble achieving/maintaining an erection, have a primary cardiovascular abnormality, have suspected primary venous leakage, or are being considered for surgical intervention
- have had other inconclusive investigations
- are candidates for surgery.
Erectile dysfunction and the patient with cardiovascular disease
Because ED may reflect more generalised arteriopathy affecting the coronary arteries, newly presenting patients should have their cardiovascular risk assessed to define them at either low or high cardiac risk. Those considered to be at intermediate cardiac risk should be re-evaluated in primary or secondary care as appropriate and redefined as either low or high cardiac risk. Patients at low cardiac risk can be managed in primary care, while those at high cardiac risk should have their assessment and management supervised by a specialist team.4 See Figure 1 for a management algorithm according to graded cardiovascular risk.
ED=erectile dysfunction; CHD=coronary heart disease
Men with ED and coronary artery disease (CAD) may be worried that the exertion and excitement of sexual intercourse may precipitate further coronary events.17 However, with appropriate education and counselling, most men with coronary heart disease (CHD) can have sex safely and use ED therapies. Vigorous sexual activity, particularly with a new partner, may be best avoided. Men at high risk of a CV event, such as those with unstable heart disease, history of recent myocardial infarction, poorly compensated heart failure, or unstable dysrhythmias, are exceptions to this.4 While nitrates are contraindicated with oral PDE5Is, these can often be substituted with an effective alternative under the advice of a cardiologist.4
Men with known CAD should be routinely asked about erectile problems.4
Erectile dysfunction and LUTS/BPH
Much evidence supports the independent association between LUTS and ED,18–21 and practitioners should bear this link in mind to:20,21
- improve understanding of the causes of both conditions
- enable patients to connect the conditions and their risk factors
- inform and direct case finding and screening practices
- help identify co-morbidities
- facilitate appropriate treatment choices.
Erectile dysfunction and depression
While recent research has shown a consistent bi-directional association between ED and depressive symptoms,22 an earlier study showed that depression at baseline did not predict incident ED, suggesting that depression is more likely to be a consequence, than a cause, of ED.23
Treatment for erectile dysfunction
The main treatment objective is to enable the man or couple to enjoy a satisfactory sexual experience.4 Lifestyle change and risk factor modification should form part of all ED management strategies.4
Any reversible causes of ED should be identified and treated appropriately. These include drug-induced ED, endocrine disorders such as TD, hyperthyroidism, or hyperprolactinaemia, and partner sexual problems.4
Erectile dysfunction due to TD may be resolved with appropriate testosterone therapy (T therapy), without the need for specific ED treatment. However, because T therapy in isolation can take many months to correct ED, a PDE5I can be prescribed to all men with ED when commencing T therapy, in the absence of any contraindications.4 A PDE5I should not be prescribed to men:24
- receiving certain drugs, including nitrates and guanylate cyclase stimulators (such as riociguat)
- in whom vasodilation or sexual activity is not recommended. This includes men with severe/unstable heart disease
- who have loss of vision in one eye because of non-arteritic anterior ischaemic optic neuropathy, regardless of whether or not this episode was in connection with previous PDE5I exposure
- with hypotension (systolic blood pressure below 90/50 mmHg)
- with unstable angina or angina occurring during sexual intercourse.
Many men develop acute ED after radical prostatectomy. Pro-erectile therapy should be started as soon as possible after this procedure.4
Psychosexual therapy may be indicated, particularly where the patient or partner feels a psychological issue is contributing to or perpetuating the problem.4
Treatment options for erectile dysfunction
To effectively manage ED, physicians must consider the efficacy and safety of the various treatment options available, together with patient and partner preference.4 See Table 1 for a summary of treatments and consult the summary of product characteristics for individual therapies.
|First-line therapies||Second-line therapies||Third-line therapies|
Oral pharmacotherapy – PDE5I
(consider tadalafil for men with ED and bothersome LUTS)
Vacuum erection devices (VEDs)
Intercavernous injection therapy (includes alprostadil and aviptadil + phentolamine)
Low-intensity extracorporeal shock wave therapy
PDE5I=phosphodiesterase inhibitor; ED=erectile dysfunction; LUTS=lower urinary tract symptoms
Phosphodiesterase inhibitors (PDE5Is). Inadequate instruction or prescribing is the main cause of treatment failure with PDE5Is, and daily or frequent dosing regimens can often salvage failures with on-demand therapy. Daily tadalafil should be considered first-line for men with ED and bothersome LUTS.4
Vacuum erection devices (VEDs) are very effective in inducing erections regardless of the cause of the ED,25–27 but satisfaction rates vary widely. Their efficacy is improved by adequate instruction, and the man and his partner having positive attitudes towards their use.4
Alprostadil intra-cavernous injections are also highly effective,28 but compliance may be an issue.29 The aviptadil/phentolamine combination has shown similar efficacy to alprostadil, with a lower incidence of post-injection pain.4,30
Intraurethral alprostadil is a less invasive but less effective treatment than the intra-cavernosal injection therapies.4
Penile prosthesis is mainly reserved for patients who have failed to respond to, or are unable to continue with, the other ED therapies. It is particularly suitable for patients with severe, organic ED.31,32 The advantages of this intervention include long-term efficacy, high satisfaction rates, removal of the requirement for ED medications, and the improved ability to lead a normal sex life.33
Erectile dysfunction can affect physical and psychosocial health, and may significantly reduce quality of life in men and their partners. While the increasing availability of effective oral medications has transformed the treatment of ED, many patients are still not being identified and treated. When men with risk factors for ED attend the clinic, physicians need to be proactive and enquire about sexual problems. Medications need to prescribed with appropriate knowledge, advice and support, and adequate doses given over appropriate durations.
After reading this article, ‘ Test and reflect ’ on your updated knowledge with our multiple-choice questions. We estimate that this activity will take you 30 minutes—worth 0.5 CPD credits.
- Increased availability of oral treatments has resulted in more men seeking help for ED, so that:
- assessment and management of ED increasingly falls to primary care
- pharmacists also have an important role in ensuring safe, appropriate prescribing
- Erectile dysfunction can affect both physical and psychosocial health
- Erectile dysfunction has similar risk factors to cardiovascular disease
- Case finding ED can help with the early diagnosis and management of several other conditions
- Erectile dysfunction is also a cardiovascular risk factor itself, conferring a risk equivalent to current moderate smoking:
- patients presenting newly with ED should be stratified for cardiovascular risk as either low or high risk, and high-risk patients managed by a specialist team
- Clinically validated questionnaires can be used for assessment and a physical examination can identify potentially reversible causes of ED
- Treatment options depend on efficacy, safety, and patient/partner preferences.
Implementation actions for STPs and ICSs
written by Dr David Jenner, GP, Cullompton, Devon
The following implementation actions are designed to support STPs and ICSs with the challenges involved with implementing new guidance at a system level. Our aim is to help you consider how to deliver improvements to healthcare within the available resources.
Appreciate that ED is not only a medical problem in itself but also a marker for other diseases, especially atherosclerotic vascular disease and prostatic disease
Establish local management algorithms for the investigation and treatment of ED and include these in local formulary and referral websites
Recognise that many men are embarrassed to present with symptoms of ED and may now wish to buy sildenafil direct from pharmacies, which may mean that they are not screened for other reversible causes of ED or possible risk factors for cardiovascular disease
Encourage local pharmacy providers to invite men to present for such screening and undertake some (history taking/blood pressure) assessment themselves
Ensure that specialist ED support services are available to help with those cases that are not responsive to basic primary care management.
STP=sustainability and transformation partnership; ICS=integrated care system; ED=erectile dysfunction
- Capogrosso P, Colicchia M, Ventimiglia E et al. One patient out of four with newly diagnosed erectile dysfunction is a young man—worrisome picture from the everyday clinical practice. J Sex Med 2013; 10: 1833–1841.
- Mobley D, Khera M, Baum N. Recent advances in the treatment of erectile dysfunction. Postgrad Med J 2017; 93: 679–685.
- Jackson G, Nehra A, Miner M et al. The assessment of vascular risk in men with erectile dysfunction: the role of the cardiologist and general physician. Int J Clin Pract 2013; 67: 1163–1172.
- Hackett G, Kirby M, Wylie K et al. British Society for Sexual Medicine guidelines on the management of erectile dysfunction in men—2017. J Sex Med 2018; 15 (4): 430–457.
- Feldman H, Goldstein I, Hatzichristou D et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts male aging study. J Urol 1994; 151 (1): 54–61.
- Thompson I, Tangen C, Goodman P et al. Erectile dysfunction and subsequent cardiovascular disease. JAMA 2005; 294 (23): 2996–3002.
- Vlachopoulos C, Terentes-Printzios D, Ioakeimidis N. Prediction of cardiovascular events and all-cause mortality with erectile dysfunction: a systematic review and meta-analysis of cohort studies. Circ Cardiovasc Qual Outcomes 2013; 6 (1): 99–109.
- Inman B, Sauver J, Jacobson D et al. A population-based, longitudinal study of erectile dysfunction and future coronary artery disease. Mayo Clin Proc 2009; 84 (2): 108–113.
- Ma R, So W, Yang X et al. Erectile dysfunction predicts coronary heart disease in type 2 diabetes. J Am Coll Cardiol 2008; 51 (21): 2045–2050.
- Dean J, McMahon C, Guay A et al. The International Society for Sexual Medicine’s process of care for the assessment and management of testosterone deficiency in adult men. J Sex Med 2015; 12 (8): 1660–1686.
- Pye S, Huhtaniemi I, Finn J et al. Late-onset hypogonadism and mortality in aging men. J Clin Endocrinol Metab 2014; 99 (4): 1357–1366.
- Rosen R, Fisher W, Eardley I. The multinational Men’s Attitudes to Life Events and Sexuality (MALES) study: I. Prevalence of erectile dysfunction and related health concerns in the general population. Curr Med Res Opin 2004; 20 (5): 607–617.
- Rosen R, Altwein J, Boyle P et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol 2003; 44 (6): 637–649.
- Oelke M, Giuliano F, Mirone V et al. Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial. Eur Urol 2012; 61 (5): 917–925.
- Seftel A, Rosen R, Kuritzky L. Physician perceptions of sexual dysfunction related to benign prostatic hyperplasia (BPH) symptoms and sexual side effects related to BPH medications. Int J Impot Res 2007; 19 (4): 386–392.
- Antonio L, Wu F, O’Neill T et al. Low free testosterone is associated with hypogonadal signs and symptoms in men with normal total testosterone. J Clin Endocrinol Metab 2016; 101 (7): 2647–2657.
- Lindau S, Abramsohn E, Bueno H et al. Sexual activity and counselling in the first month after acute myocardial infarction among younger adults in the United States and Spain. Circulation 2014; 130 (25): 2302–2309.
- Morant S, Bloomfield G, Vats V, Chapple C. Increased sexual dysfunction in men with storage and voiding lower urinary tract symptoms. J Sex Med 2009; 6 (4): 1103–1110.
- Shiri R, Häkkinen J, Koskimäki J et al. Erectile dysfunction influences the subsequent incidence of lower urinary tract symptoms and bother. Int J Impot Res 2007; 19 (3): 317–320.
- Seftel A, de la Rosette J, Birt J et al. Coexisting lower urinary tract symptoms and erectile dysfunction: a systematic review of epidemiological data. Int J Clin Pract 2013; 67 (1): 32–45.
- Kirby M, Chapple C, Jackson G et al. Erectile dysfunction and lower urinary tract symptoms: a consensus on the importance of co-diagnoses. Int J Clin Pract 2013; 67 (7): 606–618.
- Atlantis E, Sullivan T. Bidirectional association between depression and sexual dysfunction: a systematic review and meta-analysis. J Sex Med 2012; 9 (6): 1497–1507.
- Araujo A, Durante R, Feldman H et al. The relationship between depressive symptoms and male erectile dysfunction: cross-sectional results from the Massachusetts male aging study. Psychosom Med 1998; 60 (4): 458–465.
- NICE. Erectile dysfunction: phosphodiesterase-5 (PDE-5) inhibitors—prescribing information. cks.nice.org.uk/erectile-dysfunction#!prescribinginfosub (accessed 10 July 2018).
- Lewis R, Witherington R. External vacuum therapy for erectile dysfunction: use and results. World J Urol 1997; 15 (1): 78–82.
- Yuan J, Hoang A, Romero C et al. Vacuum therapy in erectile dysfunction—science and clinical evidence. Int J Impot Res 2010; 22: 211–219.
- Raina R, Agarwal A, Ausmundson S. Early use of vacuum constriction device following radical prostatectomy facilitates early sexual activity and potentially earlier return of erectile function. Int J Impot Res 2006; 18: 77–81.
- Porst H. The rationale for prostaglandin E1 in erectile failure: a survey of worldwide experience. J Urol 1996; 155 (3): 802–815.
- Mulhall J, Jahoda A, Cairney M et al. The causes of patient dropout from penile self-injection therapy for impotence. J Urol 1999; 162 (4): 1291–1294.
- Shah P, Dinsmore W, Oakes R, Hackett G. Injection therapy for the treatment of erectile dysfunction: a comparison between alprostadil and a combination of vasoactive intestinal polypeptide and phentolamine mesylate. Curr Med Res Opin 2007; 23 (10): 2577–2583.
- Montorsi F, Rigatti P, Carmignani G et al. AMS three-piece inflatable implants for erectile dysfunction: a long-term multi-institutional study in 200 consecutive patients. Eur Urol 2000; 37 (1): 50–55.
- Henry G, Jennermann C, Eid J. Evaluation of satisfaction and axial rigidity with Titan XL cylinders. Adv Urol 2012; 2012: 896070.
- NHS England. Clinical commissioning policy: penile prosthesis surgery for end stage erectile dysfunction. NHS England, 2016. Available at: www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2016/08/clinical-com-pol-16059p.pdf